Citadel Advisors’s CytomX Therapeutics CTMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$194K Buy
85,509
+85,409
+85,409% +$194K ﹤0.01% 5017
2025
Q1
$64 Sell
100
-322,211
-100% -$206K ﹤0.01% 5851
2024
Q4
$332K Buy
322,311
+5,192
+2% +$5.35K ﹤0.01% 4423
2024
Q3
$374K Sell
317,119
-177,524
-36% -$209K ﹤0.01% 4067
2024
Q2
$603K Buy
494,643
+457,866
+1,245% +$559K ﹤0.01% 3587
2024
Q1
$80.2K Sell
36,777
-216,506
-85% -$472K ﹤0.01% 5164
2023
Q4
$393K Buy
253,283
+193,117
+321% +$299K ﹤0.01% 3980
2023
Q3
$77.6K Buy
60,166
+51,312
+580% +$66.2K ﹤0.01% 4930
2023
Q2
$15.2K Sell
8,854
-269,823
-97% -$464K ﹤0.01% 5312
2023
Q1
$421K Sell
278,677
-179,241
-39% -$271K ﹤0.01% 4006
2022
Q4
$733K Buy
457,918
+408,759
+832% +$654K ﹤0.01% 3495
2022
Q3
$71K Sell
49,159
-286,830
-85% -$414K ﹤0.01% 5205
2022
Q2
$615K Buy
335,989
+321,607
+2,236% +$589K ﹤0.01% 3933
2022
Q1
$38K Sell
14,382
-23,688
-62% -$62.6K ﹤0.01% 5992
2021
Q4
$165K Buy
+38,070
New +$165K ﹤0.01% 5606
2021
Q3
Sell
-769,766
Closed -$4.87M 6458
2021
Q2
$4.87M Sell
769,766
-160,144
-17% -$1.01M ﹤0.01% 2182
2021
Q1
$7.19M Buy
929,910
+744,644
+402% +$5.76M ﹤0.01% 1713
2020
Q4
$1.21M Sell
185,266
-95,660
-34% -$626K ﹤0.01% 3057
2020
Q3
$1.87M Buy
280,926
+212,861
+313% +$1.42M ﹤0.01% 2341
2020
Q2
$567K Sell
68,065
-134,041
-66% -$1.12M ﹤0.01% 3352
2020
Q1
$1.55M Sell
202,106
-233,463
-54% -$1.79M ﹤0.01% 2457
2019
Q4
$3.62M Buy
435,569
+203,094
+87% +$1.69M ﹤0.01% 1875
2019
Q3
$1.72M Buy
+232,475
New +$1.72M ﹤0.01% 2499
2019
Q2
Sell
-34,290
Closed -$368K 4702
2019
Q1
$368K Buy
+34,290
New +$368K ﹤0.01% 3590
2018
Q4
Sell
-27,081
Closed -$501K 4554
2018
Q3
$501K Buy
27,081
+4,602
+20% +$85.1K ﹤0.01% 3162
2018
Q2
$514K Sell
22,479
-24,537
-52% -$561K ﹤0.01% 3112
2018
Q1
$1.34M Buy
+47,016
New +$1.34M ﹤0.01% 2237
2017
Q3
Sell
-31,043
Closed -$481K 3724
2017
Q2
$481K Buy
31,043
+12,927
+71% +$200K ﹤0.01% 2613
2017
Q1
$313K Buy
+18,116
New +$313K ﹤0.01% 2913